JHVEPhoto/iStock Editorial via Getty Images
Shares of Bristol-Myers Squibb (NYSE:BMY) traded lower in the premarket on Thursday after the pharma giant beat Street forecasts with its Q4 2024 results, but its 2025 outlook fell short of analysts’ expectations.
The Princeton, New Jersey-based company projected its 2025